Need access to NeoLink? Contact your Sales rep or our Client Services team at 866.776.5907, Option 3

May 21, 2025

Important reminder: All requisition orders must include the signature of an authorized representative affirming that testing is ordered by a licensed provider, and tests are medically necessary for care/treatment of the patient. Orders missing the required signature may be delayed until proper authorization is obtained. Electronic orders, such as online orders and Interface orders, will not require a handwritten signature as those are authorized electronically via their respective pre-authorized user authentication processes.

Get ready to experience innovation at the intersection of technology and patient care.

We’re excited to share with you a preview of our Neo PanTracer™ Tissue and Liquid tests. These pan-cancer assays help guide therapy selection and identify clinical trial options for patients with advanced stage solid tumors.

Schedule a meeting to learn more and be sure to visit us during the 2025 ASCO Annual Meeting.

 

 

Neo | AML Express^™

Better acute myeloid leukemia (AML) outcomes are possible when rapid, detailed genetic insights guide decision making AML Express is a next-generation sequencing (NGS)-based test that delivers class-leading turnaround time of 3-4 days and comprehensive coverage of actionable biomarkers while delivering a concise and simple report with viable diagnostic, prognostic, and predictive information. This DNA & RNA NGS assay, aligned with the latest guidelines, including the WHO 5th Edition classification, for AML, provides rapid analysis of:

• 38 genes by DNA sequencing for SNVs/InDels
• 9 genes by RNA sequencing for fusions

This allows you to make the right decision at the right time.

For more info, please contact your local NeoGenomics Territory Business Manager or visit the test menu page here.

 

Unlock potential targeted therapies for Gastric/GEJ Adenocarcinoma patients

In the United States, approximately 6% of patients with metastatic G/GEJ cancer survive 5 years post diagnosis.¹ There is an urgent need for first-line treatment options for patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.

Claudin18.2 is a NEW actionable target for patients with advanced or metastatic Gastric/GEJ Adenocarcinoma who may be eligible for biomarker-driven therapy. NeoGenomics is pleased to offer Claudin18 FDA (VYLOY®) for Gastric/GEJ Adenocarcinoma testing with a fast 2-day TAT* to maximize patient treatment outcomes. Visit our test menu page here.

1. gastriccancerbiomarkers.com
* TAT=Turnaround time

 

Your acute myeloid leukemia (AML) patients may be eligible for the IDHNow for AML Sponsored Testing Program

The IDHNow for AML Sponsored Testing Program provides no-cost rapid PCR testing to eligible patients with AML, leading to more targeted treatment options.

Patient Eligibility:

• Patient is newly diagnosed AML, and not previously treated
• Patient lives and receives treatment in the US or a US territory
• The patient does not have a known IDH1 mutation from a previous test
• The patient has not previously been tested under this program

To learn more and order today, please visit our website.